AIDS 2006 – the Sixteenth International AIDS Conference, Toronto, August 13-18 2006
AIDS 2006 News
- Making prevention work: interventions with gay men
- Making prevention work: abstinence and partner reduction reviewed at World AIDS conference
- HIV surveillance at immunisation clinics reveals weakness in KwaZulu Natal's PMTCT programme
- Safer crack-smoking resources as a viable addition to comprehensive harm reduction programs for reducing HIV and HCV transmission
- Awareness and use of HIV pre-exposure prophylaxis (PrEP) are found to be low in San Francisco gay and bisexual men
- Many HIV-positive patients in London risking their health by use of alternative therapies
- Needle-free mode of T-20 dosing looks highly satisfactory for patients
- SMART study - treatment breaks lower quality of life
- AZT/3TC before and after labour reduces HIV transmission whether infants fed with formula or breastfed and weaned early
- Splitting <i>Triomune</i> tablets for children: smallest get poorest nevirapine dose
- Gay men, methamphetamine and HIV: some issues explored at the Toronto conference
- Stress increases sexual risk-taking and risk of HIV for gay men
- Patients who need HIV therapy in London are accessing it, regardless of ethnicity or sexuality
- Alphabet of prevention technologies expanding, but no 'magical solution'
- Sexually transmitted infections increase HIV risk for gay men
- India's HIV prevalence has been 'grossly overestimated'
- Extensively drug-resistant TB rapidly fatal in South Africa
- Is serosorting working, or even possible?
- Pre-exposure prophylaxis ‘would be cost-effective’ if more than 50% efficacious
- Botswana’s adult HIV mortality rate falls since the rollout of free antiretroviral therapy
- HIV/HCV coinfected patients more prone to end-stage liver disease without treatment
- Is Uganda's HIV prevention success story 'unravelling'?
- Over 40% of HIV-infected gay men in UK unaware of status; more than half believe they are HIV-negative
- The limits of PEP: saturation knowledge does not mean saturation use
- MK-0518 integrase inhibitor effective in treatment-naive patients
- TNX-355, new entry inhibitor, effective in highly treatment-experienced patients
- Maraviroc raises CD4 counts in patients with mixed-tropism virus, may offer value for highly treatment-experienced
- Access to treatment associated with declining stigma in Botswana
- Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered
- <i>Kaletra</i> monotherapy as effective as triple therapy for at least 18 months
- Efavirenz more durable than <i>Kaletra</i> over two years in treament-naive patients
- New data shed light on poor outcome in SMART study
- Merck launches expanded access programme for integrase inhibitor
- Researchers launch hunt for people who control HIV without drugs
- Oral solution of tipranavir/ritonavir shows promise for treatment-experienced kids
- Anal cancer increases in French HIV cohort, despite use of antiretroviral therapy
- Abacavir/3TC backbone proves most durable for children over five years
- Single-dose nevirapine not jeopardising mother's treatment, large Zambian study reports
- Mixed results on ELISPOT TB testing in resource-limited settings
- Ranbaxy presents bioequivalence data on two paediatric fixed dose triple combination tablets
- High rates of TB after beginning ART in Africa — but decreases observed over time
- Sexually transmitted infections increase risk of HIV transmission in serodiscordant couples - but don't fully explain high infection rates
- Circumcision could have beneficial effect regardless of change in condom use
- US-led war on drugs 'inadvertently fuelling HIV epidemic'
- Anti-herpes therapy reduces genital and plasma HIV viral load in women not taking HIV therapy
- High prevalence of cancerous and pre-cancerous cervical cell changes in HIV-positive women in Zambian study
- First hint that PrEP might work in humans sparks debate on provision
- Darunavir/ritonavir superior virologically and immunologically to comparator drugs over one year
- Botswanan isoniazid preventative therapy trial screens out large numbers of people who are already ill
- Two-class ART just as good as three-class in the long-term, and has fewer side-effects
- ‘Opinion leader’ campaign in young black gay men achieves significant reductions in unsafe sex
- <i>Kaletra</i> monotherapy - more encouraging results
- Very low CD4, rural care, linked to higher risk of death on ARVs in African studies
- Brain problems and peripheral neuropathy under-diagnosed in Asia and the Pacific
- Randomised trial of food supplementation in food insecure patients ART inconclusive
- Selenium improves ART response in Nigerian randomised study
- Abbott cuts lopinavir price to $2200 for middle-income countries; new tablet marketed as <i>Aluvia</i>
- `Put power to prevent HIV in the hands of women`, Bill and Melinda Gates tell AIDS Conference opening
- Sexual risk-taking may be associated with MRSA in HIV-positive individuals
- Abbott cuts lopinavir price to $2200 for middle-income countries; new tablet marketed as <i>Aluvia</i>